Skip to main content
Erschienen in: International Journal of Colorectal Disease 2/2014

01.02.2014 | Original Article

Age impacts the pattern of care for elderly patients with rectal cancer

verfasst von: Florence Guillerme, Jean Baptiste Clavier, Hélène Nehme-Schuster, Valérie Leroy, Damien Heitz, Catherine Schumacher, Méher Ben Abdelghani, Cécile Brigand, Jean Emmanuel Kurtz, Georges Noël

Erschienen in: International Journal of Colorectal Disease | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study analyzed the current approaches for rectal cancer treatment in elderly patients.

Methods

We retrospectively studied 240 rectal cancer patients who had undergone radiotherapy from 2000 to 2008. The ages of the patients ranged from 65 and 75 years (group A, n = 127) and older than 75 years (group B, n = 113). The distribution of the Charlson comorbidity index was similar between the two groups, but the ECOG performance status (PS) differed between the groups (66 % of the patients of group A were PS 0, and 40 % were PS 0 in group B (p < 0.0001)). The tumor stages were comparable between groups.

Results

The median age of the patients was 74.3 years (range 65–90.6). Treatment was discussed during a multidisciplinary cancer team meeting before treatment for 55 % of the cases in group A and 73 % of the cases in group B (p < 0.001), and treatment proposals were in accordance with guidelines in 96 % of the cases in group A and 76 % of the cases in group B (p < 0.001). Group B patients received slightly less concurrent chemotherapy (35 vs. 30 % for group A; p = 0.54), more hypofractionated radiotherapy (41 vs. 54 % for group A; p = 0.064), less surgery (92 vs. 80 % for group A; p = 0.014), and less adjuvant chemotherapy (34 vs. 10 % for group A; p < 0.001). Finally, 80 % of the patients in group A and 60 % of the patients in group B received treatment in accordance with guidelines (p = 0.007) and in the logistic regression model. Non-metastatic patients who were aged below 75 years were predicted for conformal management (HR = 0.323; 95 % CI = 0.152–0.684) irrespective of their performance status, comorbidity, or disease stage.

Conclusions

Treatment proposals and administered therapy differed according to age.
Literatur
1.
Zurück zum Zitat Vercelli M, Capocaccia R, Quaglia A, Casella C, Puppo A, Coebergh JW (2000) Relative survival in elderly European cancer patients: evidence for health care inequalities. The Eurocare working group. Crit Rev Oncol Hematol 35:161–179PubMedCrossRef Vercelli M, Capocaccia R, Quaglia A, Casella C, Puppo A, Coebergh JW (2000) Relative survival in elderly European cancer patients: evidence for health care inequalities. The Eurocare working group. Crit Rev Oncol Hematol 35:161–179PubMedCrossRef
2.
Zurück zum Zitat Gross CP, McAvay GJ, Krumholz HM, Paltiel AD, Bhasin D, Tinetti ME (2006) The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med 145:646–653PubMedCrossRef Gross CP, McAvay GJ, Krumholz HM, Paltiel AD, Bhasin D, Tinetti ME (2006) The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med 145:646–653PubMedCrossRef
3.
Zurück zum Zitat Bouvier AM, Launoy G, Lepage C, Faivre J (2005) Trends in the management and survival of digestive tract cancers among patients aged over 80 years. Aliment Pharmacol Ther 22:233–241PubMedCrossRef Bouvier AM, Launoy G, Lepage C, Faivre J (2005) Trends in the management and survival of digestive tract cancers among patients aged over 80 years. Aliment Pharmacol Ther 22:233–241PubMedCrossRef
4.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRef
5.
Zurück zum Zitat Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN (2003) Ctcae v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181PubMedCrossRef Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN (2003) Ctcae v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181PubMedCrossRef
6.
Zurück zum Zitat Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5:224–237PubMedCrossRef Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5:224–237PubMedCrossRef
7.
Zurück zum Zitat Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, Escarce JJ (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383–1389PubMedCrossRef Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, Escarce JJ (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383–1389PubMedCrossRef
8.
Zurück zum Zitat Yee KW, Pater JL, Pho L, Zee B, Siu LL (2003) Enrollment of older patients in cancer treatment trials in Canada: Why is age a barrier? J Clin Oncol 21:1618–1623PubMedCrossRef Yee KW, Pater JL, Pho L, Zee B, Siu LL (2003) Enrollment of older patients in cancer treatment trials in Canada: Why is age a barrier? J Clin Oncol 21:1618–1623PubMedCrossRef
9.
Zurück zum Zitat Townsley CA, Selby R, Siu LL (2005) Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 23:3112–3124PubMedCrossRef Townsley CA, Selby R, Siu LL (2005) Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 23:3112–3124PubMedCrossRef
10.
Zurück zum Zitat Chang GJ, Skibber JM, Feig BW, Rodriguez-Bigas M (2007) Are we undertreating rectal cancer in the elderly? An epidemiologic study. Ann Surg 246:215–221PubMedCrossRef Chang GJ, Skibber JM, Feig BW, Rodriguez-Bigas M (2007) Are we undertreating rectal cancer in the elderly? An epidemiologic study. Ann Surg 246:215–221PubMedCrossRef
11.
Zurück zum Zitat Aparicio T, Navazesh A, Boutron I, Bouarioua N, Chosidow D, Mion M, Choudat L, Sobhani I, Mentre F, Soule JC (2009) Half of elderly patients routinely treated for colorectal cancer receive a substandard treatment. Crit Rev Oncol Hematol 71:249–257PubMedCrossRef Aparicio T, Navazesh A, Boutron I, Bouarioua N, Chosidow D, Mion M, Choudat L, Sobhani I, Mentre F, Soule JC (2009) Half of elderly patients routinely treated for colorectal cancer receive a substandard treatment. Crit Rev Oncol Hematol 71:249–257PubMedCrossRef
12.
Zurück zum Zitat Lemmens VE, Janssen-Heijnen ML, Verheij CD, Houterman S (2005) Comorbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg 92:615–623PubMedCrossRef Lemmens VE, Janssen-Heijnen ML, Verheij CD, Houterman S (2005) Comorbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg 92:615–623PubMedCrossRef
13.
Zurück zum Zitat Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB (2001) Who gets adjuvant treatment for stage ii and iii rectal cancer? Insight from surveillance, epidemiology, and end results–Medicare. J Clin Oncol 19:3712–3718PubMed Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB (2001) Who gets adjuvant treatment for stage ii and iii rectal cancer? Insight from surveillance, epidemiology, and end results–Medicare. J Clin Oncol 19:3712–3718PubMed
14.
Zurück zum Zitat (1997). Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish rectal cancer trial. N Engl J Med 336: 980–987. (1997). Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish rectal cancer trial. N Engl J Med 336: 980–987.
15.
Zurück zum Zitat M Fonck, JP Gekiere, C Blanc-Bisson, I Bourdel-Marchasson (2008) [state of nutrition and cancer in the elderly]. Bulletin du Cancer. 95 FMC Onco, F116-120 M Fonck, JP Gekiere, C Blanc-Bisson, I Bourdel-Marchasson (2008) [state of nutrition and cancer in the elderly]. Bulletin du Cancer. 95 FMC Onco, F116-120
16.
Zurück zum Zitat Kurtz J, Heitz D, Kurtz-Illig V, Dufour P (2009) Geriatric oncology: How far have we gone and what are the next steps? Oncology 77:147–156PubMedCrossRef Kurtz J, Heitz D, Kurtz-Illig V, Dufour P (2009) Geriatric oncology: How far have we gone and what are the next steps? Oncology 77:147–156PubMedCrossRef
17.
Zurück zum Zitat Kurtz JE, Heitz D, Serra S, Brigand C, Juif V, Podelski V, Meyer P, Litique V, Bergerat JP, Rohr S (2010) Adjuvant chemotherapy in elderly patients with colorectal cancer. A retrospective analysis of the implementation of tumor board recommendations in a single institution. Crit Rev Oncol Hematol 74:211–217PubMedCrossRef Kurtz JE, Heitz D, Serra S, Brigand C, Juif V, Podelski V, Meyer P, Litique V, Bergerat JP, Rohr S (2010) Adjuvant chemotherapy in elderly patients with colorectal cancer. A retrospective analysis of the implementation of tumor board recommendations in a single institution. Crit Rev Oncol Hematol 74:211–217PubMedCrossRef
Metadaten
Titel
Age impacts the pattern of care for elderly patients with rectal cancer
verfasst von
Florence Guillerme
Jean Baptiste Clavier
Hélène Nehme-Schuster
Valérie Leroy
Damien Heitz
Catherine Schumacher
Méher Ben Abdelghani
Cécile Brigand
Jean Emmanuel Kurtz
Georges Noël
Publikationsdatum
01.02.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 2/2014
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-013-1778-6

Weitere Artikel der Ausgabe 2/2014

International Journal of Colorectal Disease 2/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.